Analytical Data
-
Gene name
HHLA2
-
简介
HHLA2 protein, a key immune regulator, interacts with TMIGD2, providing crucial costimulation for T-cells during TCR-mediated activation. This interaction amplifies T-cell proliferation and cytokine production through an AKT-dependent signaling cascade, revealing HHLA2's role in enhancing T-cell responses and immune modulation. HHLA2 Protein, Human (HEK293, His) is the recombinant human-derived HHLA2 protein, expressed by HEK293 , with C-His labeled tag.
- Application
-
Alternative Names
HERV-H LTR-associating protein 2; Human endogenous retrovirus-H long terminal repeat-associating protein 2
-
Species
Human
-
Source
HEK293
-
Tag
C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UM44
-
Expression Region
I23-N344
-
Protein Length
Partial
-
Molecular Weight
38.4 kDa.
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HHLA2 (Human High-Loading Immunoglobulin-like Protein 2) is a member of the B7 family of immune checkpoint molecules that has garnered significant attention in cancer research due to its role in modulating immune responses. Discovered as a novel co-stimulatory molecule, HHLA2 interacts with receptors on T cells, influencing their activation and function. Unlike its better-known counterparts such as PD-1 and CTLA-4, HHLA2's specific mechanisms and impacts on cancer progression are still being elucidated. Its expression is associated with various malignancies, where it may contribute to tumor immune evasion. The production of recombinant HHLA2 protein allows for in-depth studies of its structural characteristics, binding affinities, and functional interactions with T cell receptors. This research is vital for understanding how HHLA2 can be targeted for therapeutic purposes, particularly in the development of cancer immunotherapies. By examining the potential of HHLA2 as a biomarker for tumor progression and a target for immune modulation, researchers aim to create strategies that enhance anti-tumor immunity and improve patient outcomes.
